Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2003 |
| End Date: | September 2009 |
Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration
Prostate cancer imaging using traditional anatomic modalities including CT, MR, and
ultrasound is limited. Improvement in current imaging modalities or development of new ones
should be a priority in prostate cancer research. Optimal treatment varies considerably for
patients with different staging characterizations and new imaging methods that more
accurately stage patients could lead to more appropriate treatment. The objective of this
study is to obtain preliminary, comparative data on new, promising imaging methods for
prostate cancer. PET/CT imaging using 11C-choline,11C-acetate, and Y86 or
18F-Adenosylcobalamin and MRI spectroscopy (MRS) of prostate cancer will be compared. Direct
comparison of these imaging methods has never been done and Mayo Clinic and Johns Hopkins
are uniquely able to conduct such a trial as an inter-SPORE collaboration.
ultrasound is limited. Improvement in current imaging modalities or development of new ones
should be a priority in prostate cancer research. Optimal treatment varies considerably for
patients with different staging characterizations and new imaging methods that more
accurately stage patients could lead to more appropriate treatment. The objective of this
study is to obtain preliminary, comparative data on new, promising imaging methods for
prostate cancer. PET/CT imaging using 11C-choline,11C-acetate, and Y86 or
18F-Adenosylcobalamin and MRI spectroscopy (MRS) of prostate cancer will be compared. Direct
comparison of these imaging methods has never been done and Mayo Clinic and Johns Hopkins
are uniquely able to conduct such a trial as an inter-SPORE collaboration.
Inclusion Criteria:
- Males 18 years of age or older
- Patients who have completed staging CT and/or bone scan as part of their routine
workup
- Patients with bulky metastatic prostate cancer who have 5 or more lesions suspicious
for distant metastases as determined by routine CT and/or bone scans that are
untreated by radiation
Exclusion Criteria:
- Patients who are less than 6 weeks post operative for Greenfield filter placement
- Patients with metallic surgical implants including pacemaker implants, cochlear
implants, dentures held in place by magnets imbedded in the gums and aneurysm clips
except those inserted at Mayo and only those inserted after October of 1994 and /or
metal fragments in the body including metal fragments in the eyes
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
